Blockade of programmed death-1/programmed death ligand pathway enhances the antitumor immunity of human invariant natural killer T cells

The role of invariant natural killer T (iNKT) cells in antitumor immunity has been studied extensively, and clinical trials in patients with advanced cancer have revealed a prolonged survival in some cases. In recent years, humanized blocking antibodies against co-stimulatory molecules such as PD-1...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Immunol Immunother
Autors principals: Kamata, Toshiko, Suzuki, Akane, Mise, Naoko, Ihara, Fumie, Takami, Mariko, Makita, Yuji, Horinaka, Atsushi, Harada, Kazuaki, Kunii, Naoki, Yoshida, Shigetoshi, Yoshino, Ichiro, Nakayama, Toshinori, Motohashi, Shinichiro
Format: Artigo
Idioma:Inglês
Publicat: Springer Berlin Heidelberg 2016
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5099366/
https://ncbi.nlm.nih.gov/pubmed/27631416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-016-1901-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars